More on ABBV
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $283.40 |
|
|||
| Open | $283.61 | ||||
| 52 Wk High | $68.12 | ||||
| 52 Wk Low | $50.71 | ||||
| Day High | $286.64 | ||||
| Day Low | $282.96 | ||||
| P/E | 61.91 | ||||
| EPS | $4.61 | ||||
| Volume | 5,782,663 | ||||
- AbbVie presents long-term IBD drug data at European gastroenterology meeting
- SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
- AbbVie expands board to 13, appoints UC San Diego health chief
- Form 8-K AbbVie Inc. For: Oct 14
- AbbVie Skyrizi shows endoscopic gains in Crohn's disease trial
- AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
- New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
- Abbvie (ABBV) PT Raised to $275 at UBS
- Abbvie (ABBV) PT Raised to $300 at JPMorgan
- Abbvie (ABBV) PT Raised to $290 at Cantor Fitzgerald
Entities mentioned with ABBV
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Dividend | View Related Stories »
- Show More...
